 WALTHAM, Mass., Aug. 11, 2021 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. Nasdaq: VRDN the Company or Viridian, a biopharmaceutical company advancing new treatments for patients suffering from serious diseases and underserved by current therapies, today announced financial results for the second quarter ended June 30, 2021, and provided corporate updates. 